Celcuity Inc. (NASDAQ:CELC) stock surged on Monday after the company reported topline results from the PIK3CA wild-type ...

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

We recently published These 10 Stocks are Winning Big. Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on ...

Celcuity shares skyrocketed to an all-time high when the biotech reported positive results from a Phase 3 trial of its ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

Celcuity Inc. (NASDAQ: CELC) shares soared by 210% today after the company announced highly positive topline results from its ...

US clinical-stage oncology focused biotech Celcuity saw its shares skyrocket 180% to $38.59 in early trading as it announced ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

This year's U.S. News & World Report list of top cancer hospitals includes MD Anderson Cancer Center, Memorial Sloan ...

Approval based on INAVO120 data showing the Itovebi™ (inavolisib)-based regimen more than doubled progression-free survival ...

Roche ( OTCQX:RHHBY) ( OTCQX:RHHBF) ( OTCPK:RHHVF) said that the European Commission has approved its oral cancer drug, ...